West Pharmaceutical Services, Inc. (WST) Business Profile

What it does

West Pharmaceutical Services designs and makes components used to contain and deliver injectable medicines. Its customers include biologic, generic and pharmaceutical drug makers, as well as diagnostic and medical device companies. Michele Lagarde is president and chief executive officer.

Many of West’s products sit in direct contact with a drug or help keep it contained until use. They include stoppers and seals for injectable packaging, as well as components for syringes and cartridges. The company also supplies vials, syringes, plungers and cartridges, along with systems used to mix, transfer or administer medicines. Its self-injection devices are designed for therapies patients can take at home.

West provides services alongside those components. These include laboratory testing, packaging support before a customer’s drug is approved, engineering development, regulatory expertise and technical support after a sale. It also applies films and coatings and offers washing, inspection and sterilization processes intended to address contamination and compatibility risks.

A separate contract-manufacturing business designs, makes and assembles components and devices owned by customers. These are used in applications including surgery, diagnostics, ophthalmology and drug delivery. West’s manufacturing network spans North and South America, Europe and Asia, although the locations differ between its two businesses.

How it makes money

West earns revenue by selling goods and services through two businesses. Proprietary Products supplies packaging, drug-containment components, delivery devices and associated services. Contract-Manufactured Products designs, manufactures and assembles devices and components for customers. The latter uses processes such as multi-component molding, clean-room molding and automated assembly.

In FY2025, Proprietary Products generated $2.5 billion in revenue, or 81.1% of the company total. Contract-Manufactured Products generated $582.0 million, or 18.9%.

The products can be incorporated into customers’ injectable medicines or manufacturing lines, so orders are tied to customers’ production and demand for their products. West also offers laboratory, engineering and after-sales services. Sales in a given period depend on factors including order and shipment timing, product mix, pricing, regulatory actions and competition.

Price and product mix affect profitability. In 2025, Proprietary Products gross profit rose with increased demand, particularly for high-value components, greater use of plant capacity and sales price increases. Contract-Manufactured Products gross profit fell, primarily because production costs increased. In Q3 2026, price contributed to revenue growth, and a mix shift toward high-value components helped gross margin.

West has closed the SmartDose 3.5 transaction and does not expect further product revenue from it. Its Q3 2026 West Vantage revenue declined as the roll-off of a continuous glucose monitoring program more than offset sales from new programs.

Customers and how it sells

West sells its proprietary packaging and delivery products primarily to biologic, generic and pharmaceutical drug companies. Its contract-manufacturing customers include pharmaceutical, diagnostic and medical device companies. Customers incorporate West’s components into injectable products or use contract-manufactured components in their own production lines.

Biologics accounted for 40.0% of revenue in FY2025, pharma for 24.0%, and generics for 17.0%. Contract-Manufactured Products accounted for 19.0% under the customer breakdown. West sells mainly through its own sales force and distribution network, with limited use of contract sales agents and regional distributors.

The customer base is concentrated. One customer accounted for 15.8% of consolidated net sales in 2025, with sales in both operating segments. West says losing a major customer or receiving significantly fewer orders from one could adversely affect its business.

The United States accounted for 43.3% of FY2025 revenue. West’s proprietary business has manufacturing facilities in North and South America, Europe and Asia. Its contract-manufacturing business has facilities in North America and Europe. International operations also expose the company to currency fluctuations and multiple tax jurisdictions.

Suppliers and costs

West’s main raw materials are elastomers, aluminum and plastic. Elastomers include synthetic and natural materials. The company relies on single-source suppliers for certain critical materials because of factors including availability and the quality and regulatory work involved in qualifying suppliers. It also buys some materials on open commodity markets.

West carries inventory to meet customer requirements, and some agreements require bulk purchases. To manage disruption risk, it uses measures that can include suppliers with multiple manufacturing sites, quality controls and surplus inventory. It also transfers technology among facilities to provide customers with multiple sources and use its manufacturing footprint more efficiently.

The cost of goods and services sold includes personnel, manufacturing, raw materials, freight, depreciation and facility costs. Energy is another manufacturing cost. West generally tries to pass material and energy cost increases on to customers, but there can be a delay, and competitive pressure may prevent price increases.

West has begun investing in additional high-value product finishing capacity in Europe and the United States. It considers its existing molding capacity sufficient and believes existing capacity can support current demand.

Competitive position

West competes with Datwyler and Aptar across its proprietary product lines. Competition for components centers on design and performance, quality, regulatory compliance, scientific expertise and total cost. In medical devices, West also competes with suppliers of products such as prefillable syringes and auto-injectors, as well as pharmaceutical manufacturers that can be potential customers.

In contract manufacturing, competitors range from regional businesses such as SMC Ltd. to global assembly manufacturers such as Phillips Medisize. West’s drug packaging and assembly work also competes with Sharp and PCI Pharma Services. Customers facing cost pressure can source from lower-cost locations, and West faces pricing pressure from customers and competitors.

West seeks to distinguish itself through integrated packaging and delivery systems, laboratory and engineering support, regulatory expertise, and manufacturing at multiple sites. It owns or licenses patents and other intellectual property, and exclusively licenses certain products and processes from Daikyo. West says commercial development can take several years and products can require customer acceptance and regulatory approval.

Our reading: West’s combination of technical services, regulatory expertise and components offers a meaningful competitive advantage because customers must assess compatibility and quality as well as price. Our reading: Intellectual property and development requirements provide additional protection, but their strength varies by product; West is not wholly dependent on any single intellectual property asset, license or technology. Our reading: Contract manufacturing has a less distinct moat, given the range of competitors and customer pressure to source at lower cost.

Growth opportunities

West is investing in injectable packaging, integrated containment systems, self-injection devices and drug administration products. Its Synchrony Prefillable Syringe System launched in January 2026. The company also continues to pursue acquisitions, licensing, partnerships and product development.

In 2025, sales of Westar, NovaChoice and Envision products contributed to growth in Proprietary Products. Contract-Manufactured Products benefited from increased sales of self-injection devices for obesity and diabetes, partly offset by lower diagnostic-device sales.

In Q3 2026, demand for both GLP-1 and non-GLP-1 components and upgrades drove high-value component growth. European Annex 1 regulations have driven upgrades, and West is seeing signs of upgrade activity in other regions. It added upgrade projects in 2026 and believes upgrades can support the business over multiple years.

Crystal Zenith and administration systems contributed to delivery-device growth in Q3 2026. West continues to work with partners on the next-generation SmartDose 10 self-injection system. In West Vantage, the company is shifting toward higher-value drug-handling work while legacy programs roll off and new programs ramp.

To support demand, West is expanding finishing capacity, adding and training shifts, and working to improve output from its existing facilities. It expects full-year 2026 revenue and organic sales to grow.

Structural risks

• Dependence on injectable drugs: West’s sales and profitability depend substantially on customers continuing to develop and sell injectable medicines. A move toward oral treatments or drugs requiring less frequent dosing could reduce demand for its products.
• Customer concentration and pricing: The loss of a major customer, or a substantial reduction in its orders, could hurt results. Customer consolidation and cost-control programs can also increase pricing pressure and reduce margins.
• Supply and manufacturing disruption: Some critical materials come from single sources, and regulatory requirements may make replacements slow or expensive to qualify. Certain product lines are concentrated in one or a few plants, leaving them exposed to a disruption at those facilities.
• Costs and product quality: Raw material and energy prices can fluctuate, and West may not be able to pass increases on promptly or at all. Product defects can lead to recalls, liability claims, delayed approvals and damage to its reputation.
• Technology and commercialization: New products and alternative delivery technologies from competitors could reduce demand. West’s own product development depends on customer acceptance, regulatory approvals and, for certain products, the availability of filling capacity.
• International and cyber exposure: Currency movements, tariffs and changing foreign regulations can affect operations. Cyberattacks or breaches involving West or its business partners could disrupt operations or expose confidential information.

Bottom line

Our reading

Our reading: West is primarily a supplier of components and services embedded in the production and delivery of injectable medicines, with a separate customer-owned device manufacturing business. [item1] Its technical and regulatory capabilities can help distinguish it, while growth depends on customer drug demand and the adoption of higher-value components. [item1] [call_prepared] Concentrated customers, pricing pressure and single-source materials remain important exposures. [item1] [item1a]